{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:12Z","timestamp":1780392012638,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the key projects of Natural Science Research in Universities of Jiangsu Province","award":["22KJA180006"],"award-info":[{"award-number":["22KJA180006"]}]},{"name":"the Priority Academic Program Development of Jiangsu Higher Education Institution"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62571264 and 62171236"],"award-info":[{"award-number":["62571264 and 62171236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the key project of social development in Jiangsu Province","award":["BE2022799"],"award-info":[{"award-number":["BE2022799"]}]},{"name":"Qinglan Project of Jiangsu Universities in Jiangsu Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00793-5","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:26:14Z","timestamp":1776680774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of circZFX suppresses malignant phenotypes in cholangiocarcinoma via the miR-654-3p\/HDGF and YAP1 signaling activation"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0010","authenticated-orcid":false,"given":"Tingming","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"793_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104\u201314.","journal-title":"J Hepatol"},{"issue":"9","key":"793_CR2","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejso.2019.04.002","volume":"45","author":"E Alabraba","year":"2019","unstructured":"Alabraba E, et al. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. Eur J Surg Oncol. 2019;45(9):1660\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"793_CR3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/0284186X.2017.1418532","volume":"57","author":"J Dierks","year":"2018","unstructured":"Dierks J, et al. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol. 2018;57(6):807\u201312.","journal-title":"Acta Oncol"},{"issue":"1","key":"793_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14737140.2022.1999809","volume":"22","author":"DB Hewitt","year":"2022","unstructured":"Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther. 2022;22(1):27\u201338.","journal-title":"Expert Rev Anticancer Ther"},{"key":"793_CR5","doi-asserted-by":"crossref","first-page":"p736049","DOI":"10.1155\/2015\/736049","volume":"2015","author":"P Lindner","year":"2015","unstructured":"Lindner P, Rizell M, Hafstrom L. The impact of changed strategies for patients with cholangiocarcinoma in this millenium. HPB Surg. 2015;2015:p736049.","journal-title":"HPB Surg"},{"issue":"5","key":"793_CR6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2188\/jea.JE20180007","volume":"29","author":"S Kamsa-Ard","year":"2019","unstructured":"Kamsa-Ard S, et al. Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study. J Epidemiol. 2019;29(5):197\u2013204.","journal-title":"J Epidemiol"},{"issue":"7","key":"793_CR7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","volume":"58","author":"M Strijker","year":"2019","unstructured":"Strijker M, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58(7):1048\u201355.","journal-title":"Acta Oncol"},{"issue":"6","key":"793_CR8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","volume":"221","author":"B Groot Koerkamp","year":"2015","unstructured":"Groot Koerkamp B, et al. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221(6):1041\u20139.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"793_CR9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","volume":"273","author":"WA Cambridge","year":"2021","unstructured":"Cambridge WA, et al. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Ann Surg. 2021;273(2):240\u201350.","journal-title":"Ann Surg"},{"key":"793_CR10","doi-asserted-by":"crossref","first-page":"e18761429310703","DOI":"10.2174\/0118761429310703240823045808","volume":"17","author":"B Sensi","year":"2024","unstructured":"Sensi B, et al. Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation. Curr Mol Pharmacol. 2024;17:e18761429310703.","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"793_CR11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/0113892029313473240919105819","volume":"26","author":"X He","year":"2025","unstructured":"He X, et al. CDT1 is a Potential Therapeutic Target for the Progression of NAFLD to HCC and the Exacerbation of Cancer. Curr Genomics. 2025;26(3):225\u201343.","journal-title":"Curr Genomics"},{"issue":"3","key":"793_CR12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1101\/gr.228809.117","volume":"28","author":"SK Rhie","year":"2018","unstructured":"Rhie SK, et al. ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters. Genome Res. 2018;28(3):310\u201320.","journal-title":"Genome Res"},{"issue":"11","key":"793_CR13","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1093\/nar\/gkaa384","volume":"48","author":"W Ni","year":"2020","unstructured":"Ni W, et al. Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters. Nucleic Acids Res. 2020;48(11):5986\u20136000.","journal-title":"Nucleic Acids Res"},{"issue":"1\u20132","key":"793_CR14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11010-011-1069-x","volume":"360","author":"J Fang","year":"2012","unstructured":"Fang J, et al. Knockdown of zinc finger protein, X-linked (ZFX) inhibits cell proliferation and induces apoptosis in human laryngeal squamous cell carcinoma. Mol Cell Biochem. 2012;360(1\u20132):301\u20137.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"793_CR15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00280-020-04044-w","volume":"85","author":"H Yang","year":"2020","unstructured":"Yang H, et al. Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells. Cancer Chemother Pharmacol. 2020;85(6):1183.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"793_CR16","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/ijc.28819","volume":"135","author":"KP Lai","year":"2014","unstructured":"Lai KP, et al. Overexpression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. Int J Cancer. 2014;135(8):1790\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"793_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.29252\/ibj.23.1.47","volume":"23","author":"F Pourkeramati","year":"2019","unstructured":"Pourkeramati F, et al. Differential Expression Profile of ZFX Variants Discriminates Breast Cancer Subtypes. Iran Biomed J. 2019;23(1):47\u201356.","journal-title":"Iran Biomed J"},{"issue":"8","key":"793_CR18","first-page":"636","volume":"37","author":"L Yao","year":"2022","unstructured":"Yao L, et al. Long Noncoding RNA NEAT1 Promotes the Progression of Breast Cancer by Regulating miR-138-5p\/ZFX Axis. Cancer Biother Radiopharm. 2022;37(8):636\u201349.","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"793_CR19","first-page":"637","volume":"37","author":"L Wang","year":"2022","unstructured":"Wang L, Li M, Lian R. Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p \/ ZFX axis: an in vitro and in vivo study. Histol Histopathol. 2022;37(7):637\u201354.","journal-title":"Histol Histopathol"},{"issue":"18","key":"793_CR20","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/1759-7714.14085","volume":"12","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, et al. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296\/ZFX axis. Thorac Cancer. 2021;12(18):2427\u201338.","journal-title":"Thorac Cancer"},{"issue":"1","key":"793_CR21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","volume":"25","author":"R Mu","year":"2024","unstructured":"Mu R, et al. Analysis of the Expression of PRDX6 in Patients with Hepatocellular Carcinoma and its Effect on the Phenotype of Hepatocellular Carcinoma Cells. Curr Genomics. 2024;25(1):2\u201311.","journal-title":"Curr Genomics"},{"issue":"5","key":"793_CR22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/onc.2017.361","volume":"37","author":"LS Kristensen","year":"2018","unstructured":"Kristensen LS, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555\u201365.","journal-title":"Oncogene"},{"issue":"8","key":"793_CR23","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.7150\/thno.42174","volume":"10","author":"A Huang","year":"2020","unstructured":"Huang A, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics. 2020;10(8):3503\u201317.","journal-title":"Theranostics"},{"issue":"7441","key":"793_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384\u20138.","journal-title":"Nature"},{"issue":"1","key":"793_CR25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3892\/ol.2023.14135","volume":"27","author":"X Shi","year":"2024","unstructured":"Shi X, et al. Hsa_circ_0050900 affects ferroptosis in intrahepatic cholangiocarcinoma cells by targeting hsa\u2013miR-605\u20133p to regulate SLC3A2. Oncol Lett. 2024;27(1):2.","journal-title":"Oncol Lett"},{"issue":"1","key":"793_CR26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2021.08.027","volume":"76","author":"Q Chen","year":"2022","unstructured":"Chen Q, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J Hepatol. 2022;76(1):135\u201347.","journal-title":"J Hepatol"},{"issue":"4","key":"793_CR27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163(4):811\u201328.","journal-title":"Cell"},{"key":"793_CR28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/bs.acr.2022.02.003","volume":"156","author":"S Ko","year":"2022","unstructured":"Ko S, et al. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Adv Cancer Res. 2022;156:283\u2013317.","journal-title":"Adv Cancer Res"},{"issue":"11","key":"793_CR29","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1261\/rna.043687.113","volume":"20","author":"P Glazar","year":"2014","unstructured":"Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. RNA. 2014;20(11):1666\u201370.","journal-title":"RNA"},{"issue":"1","key":"793_CR30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/15476286.2015.1128065","volume":"13","author":"DB Dudekula","year":"2016","unstructured":"Dudekula DB, et al. CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34\u201342.","journal-title":"RNA Biol"},{"issue":"1","key":"793_CR31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12038-011-9174-2","volume":"37","author":"P Nikpour","year":"2012","unstructured":"Nikpour P, et al. Differential expression of ZFX gene in gastric cancer. J Biosci. 2012;37(1):85\u201390.","journal-title":"J Biosci"},{"issue":"Suppl 1","key":"793_CR32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","volume":"39","author":"T Kendall","year":"2019","unstructured":"Kendall T, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):7\u201318.","journal-title":"Liver Int"},{"key":"793_CR33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41420-020-0247-6","volume":"6","author":"M Agostini","year":"2020","unstructured":"Agostini M, et al. The role of noncoding RNAs in epithelial cancer. Cell Death Discov. 2020;6:13.","journal-title":"Cell Death Discov"},{"issue":"2","key":"793_CR34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.gendis.2022.05.005","volume":"10","author":"X Zhong","year":"2023","unstructured":"Zhong X, et al. Circular RNA circEIF3C promotes intrahepatic cholangiocarcinoma progression and immune evasion via the miR-34a-5p\/B7-H4 axis. Genes Dis. 2023;10(2):370\u20132.","journal-title":"Genes Dis"},{"issue":"1","key":"793_CR35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41419-022-05540-y","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X, et al. CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export. Cell Death Dis. 2023;14(1):20.","journal-title":"Cell Death Dis"},{"issue":"8","key":"793_CR36","first-page":"9512","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, et al. Prognostic significance of microRNA-203 in cholangiocarcinoma. Int J Clin Exp Pathol. 2015;8(8):9512\u20136.","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"793_CR37","doi-asserted-by":"crossref","first-page":"e77623","DOI":"10.1371\/journal.pone.0077623","volume":"8","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS ONE. 2013;8(10):e77623.","journal-title":"PLoS ONE"},{"key":"793_CR38","doi-asserted-by":"crossref","first-page":"108367","DOI":"10.1016\/j.abb.2020.108367","volume":"686","author":"Y Tang","year":"2020","unstructured":"Tang Y, et al. MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6. Arch Biochem Biophys. 2020;686:108367.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"793_CR39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.29116","volume":"66","author":"H Li","year":"2017","unstructured":"Li H, et al. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. Hepatology. 2017;66(1):136\u201351.","journal-title":"Hepatology"},{"issue":"11","key":"793_CR40","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.7150\/jca.41492","volume":"11","author":"C Chen","year":"2020","unstructured":"Chen C, et al. MicroRNA-129-2-3p directly targets Wip1 to suppress the proliferation and invasion of intrahepatic cholangiocarcinoma. J Cancer. 2020;11(11):3216\u201324.","journal-title":"J Cancer"},{"issue":"12","key":"793_CR41","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/mc.23262","volume":"59","author":"S Lixin","year":"2020","unstructured":"Lixin S, et al. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Mol Carcinog. 2020;59(12):1371\u201381.","journal-title":"Mol Carcinog"},{"issue":"1","key":"793_CR42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13277-014-2651-0","volume":"36","author":"S Guo","year":"2015","unstructured":"Guo S, et al. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Tumour Biol. 2015;36(1):353\u201364.","journal-title":"Tumour Biol"},{"issue":"3","key":"793_CR43","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.3892\/mmr.2015.3922","volume":"12","author":"Y Liu","year":"2015","unstructured":"Liu Y, et al. Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells. Mol Med Rep. 2015;12(3):4713\u20139.","journal-title":"Mol Med Rep"},{"issue":"5","key":"793_CR44","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/1535-7163.MCT-08-0779","volume":"8","author":"H Ren","year":"2009","unstructured":"Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009;8(5):1106\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"793_CR45","first-page":"3919","volume":"8","author":"Y Li","year":"2015","unstructured":"Li Y, et al. High expression of Zinc-finger protein X-linked is associated with reduced E-cadherin expression and unfavorable prognosis in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8(4):3919\u201327.","journal-title":"Int J Clin Exp Pathol"},{"key":"793_CR46","doi-asserted-by":"crossref","first-page":"155551","DOI":"10.1016\/j.prp.2024.155551","volume":"262","author":"I Akrida","year":"2024","unstructured":"Akrida I, et al. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors. Pathol Res Pract. 2024;262:155551.","journal-title":"Pathol Res Pract"},{"issue":"24","key":"793_CR47","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1111\/febs.15701","volume":"288","author":"W Bassiouni","year":"2021","unstructured":"Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021;288(24):7162\u201382.","journal-title":"FEBS J"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00793-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:53:15Z","timestamp":1780390395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00793-5","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were performed according to a protocol (2021-019\u00a0M) approved by the Institutional Animal Care and Use Committee (IACUC) of Nanjing Normal University. These procedures were approved by the ethics of the First Affiliated Hospital of Nanjing Medical University. (Ethics Approval No.: 2021-SRFA-389).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}